Triggered by hyperthermia treatment at tumor sites, the PTX@TF was rapidly released and entered cancer cells, creating synergies with marimastat, thus leading to improved tumor infiltration of CD8+ (4.2-fold) and CD4+ T cells (1.7-fold). Here, CD4 is linked to neoplasm.